Jiangxi Fushine Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300497.SZ

Jiangxi Fushine Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2023: USD 349.98 M

Jiangxi Fushine Pharmaceutical Co., Ltd. Shareholders' Equity is USD 349.98 M for the year ending December 31, 2023, a -9.92% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.
  • Jiangxi Fushine Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2022 was USD 388.54 M, a -14.28% change year over year.
  • Jiangxi Fushine Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2021 was USD 453.29 M, a -1.61% change year over year.
  • Jiangxi Fushine Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2020 was USD 460.73 M, a 115.33% change year over year.
  • Jiangxi Fushine Pharmaceutical Co., Ltd. Shareholders' Equity for the year ending December 31, 2019 was USD 213.96 M, a 31.83% change year over year.
Key data
Date Shareholders' Equity Minority Interest Total Equity Total Stockholders Equity and Liabilities
Market news
Loading...
SV Wall Street
Shenzhen Stock Exchange: 300497.SZ

Jiangxi Fushine Pharmaceutical Co., Ltd.

CEO Mr. Jian Hua Bao
IPO Date Dec. 22, 2015
Location China
Headquarters No. 2, Yuli Industrial Zone
Employees 1,963
Sector Healthcare
Industries
Description

Jiangxi Fushine Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of APIs and pharmaceutical intermediates in China and internationally. The company offers penicillin, carbapenem, and other products. It also provides contract research, development, and manufacturing services. The company was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd and changed its name to Jiangxi Fushine Pharmaceutical Co., Ltd. in August 2012. Jiangxi Fushine Pharmaceutical Co., Ltd. was founded in 2002 and is based in Jingdezhen, China.

StockViz Staff

February 2, 2025

Any question? Send us an email